FREE LIVE WEBCASTS

Data Management and Integration for the Future of Clinical Trials
Tuesday, November 10, 2009 at 11:00 AM EST

The integration of data from the various technologies employed in clinical trials continues to increase in complexity. The typical clinical trial today integrates data from IVR, EDC, ePRO & Laboratories, to name but a few. Achieving a seamless integration of data greatly improves the speed at which data is available, enhances the quality and consistency of that data, and reduces costs. The pharmaceutical industry continues to strive for this efficiency while reducing the cost of getting drugs to market. Outsourcing drug development to CRO's using the latest technology platforms is a key strategy in this quest. This webcast will explore how a leading pharmaceutical company and ICON used the latest electronic data capture technology to efficiently integrate all critical data sources, ultimately enabling the continuous assessment of patient data.

Register Free at www.appliedclinicaltrialsonline.com/future

Sponsor:
Oracle Health Sciences

ON-DEMANDS NOW AVAILABLE FOR REPLAY

Optimize Your Patient Enrollment for Clinical Trials with Predictive Analytics
Recorded on: October 21, 2009

Significant technology advancements have allowed R&D teams the ability to access real time study level data. However, we lack a consistent, transparent and predictable method of planning and forecasting for major milestones associated with enrollment performance. Predictive analytics are key to the future of enrollment planning optimization and offer:

• A simplistic, strategic and data driven process for clinical enrollment planning
  

• A consistent methodology that translates easily between middle and upper management
  

• An opportunity to see real time and ongoing impact of actual performance to date on key milestones
  

• The ability to model multiple scenarios for impact against timelines prior to implementing a solution

Sponsor:
DecisionView

New R&D Trends & Emerging Business Models for Contract Research Organizations
Recorded on: October 20, 2009

With R&D productivity on the decline, managing growth and opportunity in today's turbulent Life Sciences market is among the greatest challenges facing the CRO industry. To address this challenge, the CRO industry must be able to quickly transform to capitalize on new opportunities designed to streamline existing information technology and business operations, while at the same time expanding access to best of breed software applications to improve performance and reduce overall infrastructure costs. This session will provide valuable insight on outsourcing trends and innovative business models designed for CROs to capitalize on today's emerging market conditions and the associated benefits to sponsors.

Key Learning Objectives:

• Creating an environment for data transparency
  

• Benefits of standardizing business processes on a common application platform
  

• Establishing a flexible business application architecture that is open, integrated and complete

Sponsor:
Oracle Health Sciences

An Evolving Standard for Success: Proving Product Value Through Comparative Effectiveness Data
Recorded on: September 10, 2009

Inclusion of $1.1B in the Obama Stimulus Plan to support comparative effectiveness research of drugs, medical devices, surgical procedures and other treatments, is a clear indication of the US Government's priority to obtain value in healthcare dollar spending. As it gains traction among policymakers, and as the Federal Government continues to increase its role as the largest direct payer for drugs, biologics, devices and diagnostics, we expect regulators to demand such data for new products demonstrating greater benefits over existing products. In this webcast learn: the definition of comparative effectiveness, and an overview of the current US regulatory status, and outlook for future state. In addition to how comparative effectiveness data is generated and utilized in product development and post-marketing, and how to develop a prioritized plan of action to assess and analyze your product portfolio: early stage through marketed products.

Register Free at www.appliedclinicaltrialsonline.com/comparativeeffectiveness

Sponsor:
PAREXEL

Clinical Study Data Integration - the Art and the Promise
Recorded on: July 8, 2009

In the life sciences industry, the process of clinical development requires that patient data collected from multiple sources be merged and combined for the purpose of understanding the safety and efficacy of a compound. Quick and accurate access to this combined data can:

• Inform management decisions to alter, accelerate, or cancel the development of a particular compound and thus increase profits
• Deliver data for formal structured analysis to accelerate regulatory submissions
• Minimize the risk of introducing an unsafe compound to the market

Register Free at www.appliedclinicaltrialsonline.com/integration

Sponsor:
Oracle Health Sciences

The Unvarnished Truth about Comparative Effectiveness
Recorded on: June 25, 2009

The mere mention of the term "comparative effectiveness" evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. President Obama has called for a national agency for comparative effectiveness. Congress introduced a bill in summer 2008 that would have set the stage for comparative effectiveness at a federal level. No one doubts that comparative effectiveness is coming to healthcare - but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare? More

Register Free at www.pharmexec.com/effectiveness

Sponsor:
AmerisourceBergen Specialty Group

Data driven laboratory asset management programs - Unlock unknown capital and drive efficiency while improving quality and scientist experience
Recorded on: June 17, 2009

With increasing pressure in the pharmaceutical and biotech industry to reduce the costs of developing new drugs, more companies are looking at consolidating suppliers and partnering with global providers to enable them gain economies of scale, unify processes and increase productivity across all sites and functions. More companies are starting to focus on their laboratory assets, how these are maintained, how validation is carried out, how downtime affects their operations and scientists' productivity, how those assets are being utilized and whether they have over/under capacity. Our lifecycle asset management programs go well beyond asset maintenance and provide you with a future proof solution that will improve scientist productivity, support capital investment strategies, help drive efficiency through multiple functions without compromising quality or scientist experience.

Register Free at www.pharmexec.com/datadriven

Sponsor:
GE Healthcare

Video: Early Phase Strategies to Increase the Success of Later Phase Trials
Recorded on: May 27, 2009

Many pharmaceutical and biotech organizations miss the opportunity to develop Early Phase strategies to transition to Later Phase success. For example, 41% of all New Drug Applications (NDAs) fail due to insufficient information on the optimal dose. By including "real patient" populations in Phase I/IIa studies, these organizations could: Obtain data from the type of patients who will eventually be used in Phase III trials. Devise population modeling and simulation techniques to eliminate the effects of co-variates and improve Proof-of-Concept.

Register Free at www.pharmexec.com/earlyphase

Sponsor:
Quintiles

Wanted: A Single Version of the Truth for Your Customer Data
Recorded on: May 20, 2009

The Life Sciences industry faces many challenges as they close out the first decade of the new millennium. Well documented as one of the most highly regulated Industries, companies are faced with maintaining compliance while operating in an era of corporate downsizing. The solution is rooted in the often underestimated area of master data management. Join us for this free live webcast, featuring a panel of industry experts who will share practical insights to help you improve your business processes starting from their very foundation.

Register Free at www.pharmexec.com/truth

Sponsor:
Cegedim Dendrite

Video: Transforming Sales & Marketing Given Today's Pharma Realities: A New Model for Success
Recorded on: May 12, 2009

The world’s top pharmaceutical markets have hit maturity. Growth has slowed, especially in primary care, and companies are shifting to a specialty focus. Have your sales and marketing strategies adapted to this new reality? Over the past decade, and especially over the last three years, the largest pharma markets have been utterly transformed. Tried and true strategies can no longer keep up. Across the industry, executives are asking:
Exactly how much are companies overspending on promotion or misdirecting budgets to unproductive activities?
What are the implications of this as they look for way to further cut costs and reduce infrastructure?
Which commercial model will make the most efficient use of resources given rising consumer and payer demand, increased competition/genericization and a growing specialty product focus?

Register Free at www.pharmexec.com/commercialmodels

Sponsor:
IMS Health

Understanding the Complexities of State Licensing and VAWD
Recorded on: April 21, 2009

The changing environment surrounding the requirements for state licensure of manufacturers and wholesalers can be difficult to understand. Knowing the importance and your responsibility surrounding VAWD and the definitions around "wholesaler" and "manufacturer" are unclear to many companies. Join us to discuss industry challenges, and hear from experts who have successfully managed the complexities and dynamics of state licensure. Hear what is being done as an industry to understand and monitor the complex database of rules and regulations that define "wholesale distribution". And learn about cost effective solutions to ensure compliance with state licensing requirements and how to best stay current with future legislative changes in this complex environment.

Register Free at www.pharmexec.com/VAWD

Sponsor:
Cegedim Dendrite

Revolutionizing KOL Relationship Management for Maximum Impact
Recorded on: February 24, 2009

2009 promises to bring increased regulatory and financial scrutiny to the life sciences industry as new regulations and public health policy reforms loom on the horizon. This will force pharmaceutical companies to change the ways they interact with key physicians and opinion leaders in an effort to increase transparency and ethical outcomes.  To address these issues, a forward-thinking Key Opinion Leader (KOL) Management strategy is required to ensure regulatory compliance that enables knowledge sharing, communication, and visibility. As a result, your team will develop trusted, credible scientific peer relationships between your company, your MSLs and thought leaders. click here.

Register Free at www.pharmexec.com/KOL

Sponsor:
Cegedim Dendrite

No More Tiers! A New Approach for Evaluating Formulary Contracts
Recorded on: February 11, 2009

Since the adoption of three tier benefit designs by insurers and PBMs in the early 1990’s, Pharmaceutical Executives have argued about the value of contracting for preferred (Tier 2) status for their brands. Managed care executives within Pharma have been measured primarily in terms of the percent of lives having Tier 2 access. Brands and sales forces have blamed a lack of Tier 2 access for not achieving their uptake goals. But what is that Quality of Access for Tier 2, how has it changed over time and how much does it actually differ from Tier 3? Where does it differ significantly? Does it matter? Does it matter enough to pay the rebates expected by Managed Care plans? click here.

Register Free at www.pharmexec.com/tiers

Sponsor:
Amundsen Group and Wolters Kluwer Health

Using Patient Adherence programs to Prove the Value of your Brands for today´s Payor Marketplace
Recorded on: January 30, 2009

Pharma is facing a new reality: As never before, key customers—from prescription drug plans to government to large medical practices—are demanding data on patient outcomes. As pharma companies scramble to meet these new expectations many are ignoring a powerful data source that they may already have developed: their own patient adherence programs. Patient adherence programs are a vital part of pharma companies’ strategy today, and their value is all the greater when they can be used to generate data that supports the value of brands. For hands-on, up-to-date insight on how to coordinate these two goals for the benefit of patients and brand alike, we urge you to attend this new, live webcast, featuring industry experts in both compliance and marketing. click here.

Register Free at www.pharmexec.com/payormarketplace

Sponsor:
Innovex